Vancouver, British Columbia, September 26, 2025 – Rocket Doctor AI Inc. (the “Company” or “Rocket Doctor AI”) (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) announces that it has filed a prospectus supplement dated September 22, 2025 (the “Prospectus Supplement”) to its short form base shelf prospectus dated June 10, 2024 (the “Shelf Prospectus”) to qualify the distribution of securities underlying 3,677,400 special warrants (the “Special Warrants”) issued by the Company on August 21, 2025 (the “Offering”).
The Prospectus Supplement qualifies the distribution of 3,677,400 common shares (each a “Common Share”) and 3,677,400 common share purchase warrants (each a “Warrant”) comprising the units of the Company issuable on the exercise or deemed exercise of the Special Warrants in the Provinces of British Columbia, Alberta, and Ontario. Each Warrant entitles the holder thereof to acquire one Common Share at an exercise price of $0.75 until 5:00 p.m. (Pacific Time) for a period of 12 months from the date of issuance.
The Special Warrants will be deemed to be converted into Common Shares and Warrants on October 2, 2025. No action is required on the part of any holder of Special Warrants to convert their Special Warrants into underlying securities.
The qualification rights of holders of Special Warrants are further described in the Prospectus Supplement and the Shelf Prospectus, which can be found under the Company’s profile on SEDAR+ at a www.sedarplus.ca.
Access to the Shelf Prospectus and the Prospectus Supplement, and any amendment to the documents, is provided in accordance with securities legislation relating to procedures for providing access to a shelf prospectus supplement, a base shelf prospectus and any amendment. The Shelf Prospectus and the Prospectus Supplement are accessible on SEDAR+ at www.sedarplus.ca. An electronic or paper copy of the Prospectus Supplement, the corresponding Shelf Prospectus and any amendment to the documents may be obtained, without charge, from the Company by email at info@rocketdoctor.ai and by providing the contact with an email address or address, as applicable.
The securities issued pursuant to the Offering have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.
